Agenus initiates botensilimab phase 2 activate trials in advanced mss colorectal cancer and advanced melanoma

Lexington, mass., sept. 12, 2022 (globe newswire) -- agenus (nasdaq: agen), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced the initiation of a global phase 2 program of botensilimab, an fc-enhanced anti-ctla-4 that activates innate and adaptive immune responses. these trials include activate-colorectal, a phase 2 study designed to evaluate botensilimab as monotherapy and in combination with balstilimab (anti-pd-1) for the treatment of microsatellite stable colorectal cancer (mss crc), and activate-melanoma, a phase 2 study designed to evaluate botensilimab as a single agent for advanced melanoma, refractory to either prior anti-pd-1 or combined anti-pd-1/anti-ctla-4 therapy. an additional phase 2 study in pancreatic cancer is anticipated to begin later in 2022.
AGEN Ratings Summary
AGEN Quant Ranking